Our portfolio company Thermosome has presented encouraging initial clinical data from its Phase I Trial of its lead compound THE001 in patients with heavily pre-treated, locally advanced unresectable or metastatic soft tissue sarcoma (STS).
Besides safety and tolerability in the first two dose levels, the drug development company demonstrated encouraging signs of clinical activity of this novel treatment.
Data presented at the 2024 Annual Meeting of the Connective Tissue Oncology Society (CTOS) in San Diego showed THE001 to be safe and well tolerated at the first two dose levels (20 mg/m² and 40 mg/m²), with no formulation-related adverse events reported. Of particular note, 5 of 6 efficacy-evaluable patients achieved local disease control and 4 maintained stable disease according to RECIST criteria.
More information in the press release under the following link
More about Thermosome
